Saltar al contenido
Merck

The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain.

Bioorganic & medicinal chemistry (2018-12-13)
Alan D Brown, Sharan K Bagal, Paul Blackwell, David C Blakemore, Bruce Brown, Peter J Bungay, Martin Corless, James Crawforth, David Fengas, David R Fenwick, Victoria Gray, Mark Kemp, Wolfgang Klute, Laia Malet Sanz, Duncan Miller, Yoshihisa Murata, C Elizabeth Payne, Sarah Skerratt, Edward B Stevens, Joseph S Warmus
RESUMEN

The voltage gated sodium channel NaV1.8 has been postulated to play a key role in the transmission of pain signals. Core hopping from our previously reported phenylimidazole leads has allowed the identification of a novel series of benzimidazole NaV1.8 blockers. Subsequent optimization allowed the identification of compound 9, PF-06305591, as a potent, highly selective blocker with an excellent preclinical in vitro ADME and safety profile.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
PF-06305591 dihydrate, ≥98% (HPLC)